Table 1.
Basic features of included literature
| Studies | Diagnosis | Study design | Number of researchers | Ages | Intervention | Outcome | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| E/C | E/C | E | C | ||||
| Liang N 2019 [9] | HR-HPV(+) | Random | 30/30 | 35.4±4.2/35.6±1.1 | Based on C group + Baofukang, 1.74 g/d, qd, 15 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 8×105 IU/d, qd, 9 days/courses, for 3 courses (ad us, ext) | ①② |
| Fang Y 2021 [10] | HPV(+) | Random number table | 50/50 | 42.29±6.37/42.31±6.28 | Based on C group + Baofukang, 1.74 g/d, qod, for 3 months (ad us, ext) | rhIFN-α2b, 5×105 IU/d, qod, 12 days/courses, for 3 courses (ad us, ext) | ①② |
| Zhu W 2020 [11] | HPV(+) | Random number table | 42/42 | 32.45±3.39/32.51±3.31 | Based on C group + Baofukang, 1.74 g/d, qd, 18 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 10 g/d, qd, 18 days/courses, for 3 courses (ad us, ext) | ①③ |
| Huang J 2017 [12] | HR-HPV(+) | Random | 40/40 | 35.31±2.13/35.25±2.45 | Based on C group + Baofukang, 1.74 g/d, qd, for 3 weeks (ad us, ext) | rhIFN-α2b, 1×105 IU/d, qd, for 3 weeks (ad us, ext) | ① |
| Yang J 2016 [13] | HR-HPV(+) | Random number table | 73/73 | 35.56±4.39/35.79±4.42 | Based on C group + Baofukang, 1.74 g/d, qd, 15 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 8×105 IU/d, qd, 9 days/courses, for 3 courses (ad us, ext) | ①② |
| Wu Y 2015 [14] | HR-HPV(+) | Random number table | 35/35 | 34.6±4.1/33.9±4.3 | Based on C group + Baofukang, 3.48 g/d, qod, for 3 months (ad us, ext) | rhIFN-α2b, 10 g/d, qod, for 3 months (ad us, ext) | ① |
| Shun X 2022 [15] | HPV(+) | Random number table | 150/150 | 45.39±3.75/45.36±3.74 | Based on C group + Baofukang, 1.74 g/d, qd, for 3 months (ad us, ext) | rhIFN-α2b, 1 g/d, for 3 months (ad us, ext) | ①③ |
| Li C 2018 [16] | HR-HPV(+) | Random | 100/100 | 36.62±2.19/35.92±2.61 | Based on C group + Baofukang, 3.48 g/d, qod, 16 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 10 g/d, qd, 16 days/courses, for 3 courses (ad us, ext) | ①②③ |
| Liu H 2016 [17] | HR-HPV(+) | Random | 60/60 | 39.3±4.1/39.23±4.16 | Based on C group + Baofukang, 3.48 g/d, qod, for 2 weeks (ad us, ext) | rhIFN-α2b, 10 g/d, qod, 10 times/courses, for 3 courses (ad us, ext) | ①②③ |
| Lai Z 2021 [18] | HR-HPV(+) | Random | 39/39 | 46.2±3.5/42.2±3.5 | Based on C group + Baofukang, 1.74 g/d, qod, 10 times/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 5×105 IU/d, qod, 10 times/courses, for 3 courses (ad us, ext) | ①②③ |
| Li X 2020 [19] | HR-HPV(+) | Random number table | 35/35 | 35.3±5.0/36.3±4.4 | Based on C group + Baofukang, 1.74 g/d, qod, 10 times/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 1×105 IU/d, qod, 10 times/courses, for 3 courses (ad us, ext) | ③ |
| Wang L 2021 [20] | HR-HPV(+) | Random number table | 60/60 | 35.26±4.86/35.56±5.10 | Based on C group + Baofukang, 1.74 g/d, qod, 10 times/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 1 ga time, qod, 10 times/courses, for 3 courses (ad us, ext) | ①②③ |
| Lai X 2022 [21] | HR-HPV(+) | Random | 40/40 | 35.12±4.08/35.32±4.31 | Based on C group + Baofukang, 3.48 g/d, qod, 16 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 8×105 IU/d, qd, 16 days/courses, for 3 courses (ad us, ext) | ①②③ |
| Yi B 2021 [22] | HPV(+) | Random number table | 109/109 | 38.9±6.7/38.6±6.6 | Based on C group + Baofukang, 1.74 g/d, qd, 10 days/courses, for 3 courses (ad us, ext) | rhIFN-α2b, 8×105 IU/d, qd, 10 days/courses, for 3 courses (ad us, ext) | ①②③ |
| Zhou J 2020 [23] | HPV(+) | Grouped by medication | 30/30 | 38.86±2.95/37.24±2.35 | Based on C group + Baofukang, 1.74 g/d, qd, for 3 months (ad us, ext) | rhIFN-α2b, 10 g/d, qd, for 3 months (ad us, ext) | ① |
Notes: HR-HPV stands for high-risk human papillomavirus infection; E stands for experimental group; C stands for control group; qd stands for once a day; qod stands for once every other day; ad us, ext stands for external use; ① stands for total effectiveness of treatment; ② stands for HPV clearance rate; ③ stands for adverse reaction rate.